uniQure NV Company Profile (NASDAQ:QURE)

About uniQure NV

uniQure NV logoUniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Company's first product is Glybera, for the treatment of lipoprotein lipase deficiency (LPLD). In the clinical pipeline, it has gene treatments for hemophilia, porphyria, Parkinson, Sanfilippo B syndrome and hearing loss. Additionally, it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform, including a cost effective manufacturing process. In August 2014, Uniqure NV acquired InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: QURE
  • CUSIP:
Key Metrics:
  • Previous Close: $8.25
  • 50 Day Moving Average: $7.88
  • 200 Day Moving Average: $11.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.84
  • P/E Growth: 0.00
  • Market Cap: $204.76M
  • Outstanding Shares: 24,819,000
  • Beta: 0.19
Additional Links:
Companies Related to uniQure NV:

Analyst Ratings

Consensus Ratings for uniQure NV (NASDAQ:QURE) (?)
Ratings Breakdown: 10 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.11 (252.86% upside)

Analysts' Ratings History for uniQure NV (NASDAQ:QURE)
Show:
DateFirmActionRatingPrice TargetDetails
8/19/2016Piper Jaffray Cos.Set Price TargetBuy$26.00 -> $16.00View Rating Details
8/4/2016HC WainwrightInitiated CoverageBuy$21.00View Rating Details
8/2/2016Leerink SwannReiterated RatingPositive$27.00View Rating Details
7/28/2016Jefferies GroupSet Price TargetBuy$28.00View Rating Details
7/28/2016Chardan CapitalSet Price TargetBuy$35.00View Rating Details
7/28/2016Cowen and CompanyReiterated RatingBuyView Rating Details
6/15/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$23.00View Rating Details
6/15/2016WallachBeth CapitalLower Price TargetBuy$60.00 -> $35.00View Rating Details
1/8/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details
1/8/2016Roth CapitalReiterated RatingBuy$37.00View Rating Details
5/9/2015BMO Capital MarketsReiterated RatingOutperform -> PositiveView Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for uniQure NV (NASDAQ:QURE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/25/2016($0.89)N/AView Earnings Details
5/31/2016Q1($0.82)($0.93)ViewN/AView Earnings Details
4/4/2016Q415($0.60)($0.58)ViewN/AView Earnings Details
11/30/2015Q315($0.64)($1.14)ViewListenView Earnings Details
8/27/2015Q215($0.56)($0.98)ViewN/AView Earnings Details
6/11/2015Q1($0.82)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details
4/6/2015($0.62)($0.77)ViewN/AView Earnings Details
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details
9/2/2014Q214($0.55)($1.35)ViewN/AView Earnings Details
6/6/2014($0.45)($0.52)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for uniQure NV (NASDAQ:QURE)
Current Year EPS Consensus Estimate: $-3.50 EPS
Next Year EPS Consensus Estimate: $-2.90 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.94)($0.63)($0.75)
Q2 20163($0.98)($0.74)($0.85)
Q3 20163($1.00)($0.77)($0.87)
Q4 20163($1.03)($0.80)($0.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for uniQure NV (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for uniQure NV (NASDAQ:QURE)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for uniQure NV (NASDAQ:QURE)
DateHeadline
News IconIs uniQure N.V. (NASDAQ:QURE) a Buy According to the Crowd? - Post News (NASDAQ:QURE)
www.kentuckypostnews.com - August 23 at 7:10 PM
News IconStock Moving Up in Session: uniQure N.V. (NASDAQ:QURE) - Post News (NASDAQ:QURE)
www.kentuckypostnews.com - August 22 at 6:56 PM
globenewswire.com logouniQure to Present at Upcoming Investor Conferences in September - GlobeNewswire (press release) (NASDAQ:QURE)
globenewswire.com - August 17 at 7:23 PM
finance.yahoo.com logouniQure to Present at Upcoming Investor Conferences in September (NASDAQ:QURE)
finance.yahoo.com - August 17 at 10:03 AM
News IconOne of the Best Biotech Stocks to Buy Could Return 52% in One Year (NASDAQ:QURE)
moneymorning.com - August 3 at 7:24 PM
thecountrycaller.com logoPfizer Inc. (PFE) to Explore Gene Therapy Portfolio (NASDAQ:QURE)
www.thecountrycaller.com - August 2 at 12:00 PM
nasdaq.com logoPfizer To Acquire Gene-Tech Company -- WSJ (NASDAQ:QURE)
www.nasdaq.com - August 2 at 12:00 PM
News IconPfizer acquires Bamboo Therapeutics (NASDAQ:QURE)
www.tradearabia.com - August 2 at 12:00 PM
News IconPfizer acquires Bamboo Therapeutics in $645 million deal (NASDAQ:QURE)
www.poandpo.com - August 1 at 6:49 PM
fortune.com logoPfizer Just Spent about $645 Million to Buy This Gene Therapy Company (NASDAQ:QURE)
fortune.com - August 1 at 6:49 PM
nasdaq.com logoPfizer to Buy Gene Therapy Company Bamboo Therapeutics (NASDAQ:QURE)
www.nasdaq.com - August 1 at 6:49 PM
marketwatch.com logoPfizer to buy gene therapy company Bamboo (NASDAQ:QURE)
www.marketwatch.com - August 1 at 11:43 AM
News IconPfizer acquires Bamboo Therapeutics to beef up gene therapy arsenal (NASDAQ:QURE)
www.channelnewsasia.com - August 1 at 11:43 AM
streetinsider.com logouniQure (QURE) Announces Updated Data from Ongoing Phase I/II trial of AMT-060 - StreetInsider.com (NASDAQ:QURE)
www.streetinsider.com - July 28 at 10:19 AM
reuters.com logoBRIEF-Uniqure presents updated clinical data in patients with severe Hemophilia B - Reuters (NASDAQ:QURE)
www.reuters.com - July 28 at 10:19 AM
publicnow.com logouniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect (NASDAQ:QURE)
www.publicnow.com - July 27 at 2:28 PM
ftsenews.co.uk logoNew Broker Ratings For Uniqure BV (NASDAQ:QURE) - FTSE News (NASDAQ:QURE)
www.ftsenews.co.uk - July 25 at 7:11 PM
News IconuniQure N.V. (NASDAQ:QURE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:QURE)
www.engelwooddaily.com - July 21 at 7:23 PM
News IconEPS Roundup: BJ's Restaurants, Inc. (NASDAQ:BJRI), uniQure N.V. (NASDAQ:QURE), Six Flags Entertainment ... - Engelwood Daily (NASDAQ:QURE)
www.engelwooddaily.com - July 20 at 7:54 PM
News IconEquity Roundup: Stock Performance Focus on uniQure N.V. (NASDAQ:QURE) - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - July 20 at 9:52 AM
News IconAs Gene Therapies Disrupt Big Pharma, Here's How to Get Your Piece of the Action (NASDAQ:QURE)
moneymorning.com - July 19 at 7:10 PM
News IconHow Many Uniqure NV (NASDAQ:QURE)'s Analysts Are Bearish? - Consumer Eagle (NASDAQ:QURE)
www.consumereagle.com - July 19 at 8:00 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for uniQure N.V. (NASDAQ:QURE) - TGP (NASDAQ:QURE)
telanaganapress.com - July 19 at 8:00 AM
fiscalstandard.com logoUniqure BV (NASDAQ:QURE) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:QURE)
www.fiscalstandard.com - July 17 at 6:27 PM
News IconUniqure NV Ord (NASDAQ:QURE) Shorted Shares Increased 4.23% After Market Selling - Consumer Eagle (NASDAQ:QURE)
www.consumereagle.com - July 17 at 6:27 PM
News IconUniqure NV Just Recorded A Sigfniciant Decline - Consumer Eagle (NASDAQ:QURE)
www.consumereagle.com - July 16 at 6:31 PM
investornewswire.com logoWill uniQure N.V. (NASDAQ:QURE) Surprise Analysts? - Investor Newswire (NASDAQ:QURE)
www.investornewswire.com - July 14 at 10:40 AM
News IconAnalyst Target and Average Rating Watch: uniQure N.V. (NASDAQ:QURE) - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - July 14 at 10:40 AM
finance.yahoo.com logouniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress (NASDAQ:QURE)
finance.yahoo.com - July 11 at 1:54 PM
reuters.com logoBRIEF-UniQure appoints Jonathan Garen as chief business officer - Reuters (NASDAQ:QURE)
www.reuters.com - July 9 at 6:25 PM
News IconUniqure NV Ord (NASDAQ:QURE) Sellers Increased By 4.23% Their Shorts - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - July 8 at 9:56 AM
news.cmlviz.com logouniQure NV Stock Momentum at Critical Inflection Point - CML News (NASDAQ:QURE)
news.cmlviz.com - July 8 at 9:56 AM
News IconCompany Stock Focus for uniQure N.V. (NASDAQ:QURE): Which Way Will Shares Head? - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - July 7 at 9:51 AM
smarteranalyst.com logoCompany Update (NASDAQ:QURE): Uniqure NV Appoints Jonathan Garen as Chief Business Officer - Smarter Analyst (NASDAQ:QURE)
www.smarteranalyst.com - July 7 at 9:51 AM
publicnow.com logouniQure Appoints Jonathan Garen as Chief Business Officer (NASDAQ:QURE)
www.publicnow.com - July 7 at 7:31 AM
News IconAre Analysts Bearish Uniqure NV (NASDAQ:QURE) After Last Week? - Engelwood Daily (NASDAQ:QURE)
www.engelwooddaily.com - July 4 at 6:13 PM
News IconIt Seems Uniqure NV Will Go Up. Have Another Big Increase - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - July 4 at 6:13 PM
prnewswire.com logoProtein Sciences Announces Exclusive License to uniQure of Cell Line and Technology for Production of Human Gene ... - PR Newswire (press release) (NASDAQ:QURE)
www.prnewswire.com - June 30 at 9:51 AM
News IconCovering the Bases on uniQure N.V. (NASDAQ:QURE): Where is the Stock Going? - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - June 30 at 9:51 AM
News IconDiscover the amyotrophic lateral sclerosis pipeline landscape and therapeutics under development market review 2016 (NASDAQ:QURE)
www.whatech.com - June 28 at 6:56 PM
prnewswire.com logoProtein Sciences Announces Exclusive License to uniQure of Cell Line and Technology for Production of Human Gene Therapies (NASDAQ:QURE)
www.prnewswire.com - June 28 at 11:52 AM
globenewswire.com logouniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications - GlobeNewswire (press release) (NASDAQ:QURE)
globenewswire.com - June 27 at 6:59 PM
News IconuniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations Communications - EconoTimes (NASDAQ:QURE)
www.econotimes.com - June 27 at 6:59 PM
kcregister.com logoBiotechnology Decliners: uniQure N.V. (NASDAQ:QURE), ImmunoGen, Inc. (NASDAQ:IMGN), Alexion Pharmaceuticals ... - KC Register (NASDAQ:QURE)
www.kcregister.com - June 24 at 9:39 AM
News IconuniQure N.V. (NASDAQ:QURE) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:QURE)
www.engelwooddaily.com - June 24 at 9:39 AM
News IconCould Uniqure NV See a Reversal After This Very Weak Session? - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - June 24 at 9:39 AM
News IconUniqure NV Ord (NASDAQ:QURE) Sellers Covered 4.69% of Their Shorts - Press Telegraph (NASDAQ:QURE)
presstelegraph.com - June 24 at 9:39 AM
kcregister.com logoTrader's Watch List: uniQure N.V. (NASDAQ:QURE), Bon-Ton Stores Inc. (NASDAQ:BONT), Rite Aid (NYSE:RAD ... - KC Register (NASDAQ:QURE)
www.kcregister.com - June 21 at 11:23 AM
seekingalpha.com logoNew Data Spark Hemophilia B Gene Therapy Battle - Seeking Alpha (NASDAQ:QURE)
seekingalpha.com - June 17 at 6:49 PM
directorstalkinterviews.com logoUniqure NV 271.2% Potential Upside Now Implied by WallachBeth - DirectorsTalk Interviews (NASDAQ:QURE)
www.directorstalkinterviews.com - June 15 at 6:57 PM

Social

uniQure NV (NASDAQ:QURE) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff